Depression, bone loss, and other conditions linked to low testosterone

Low testosterone, clinically male hypogonadism, is linked to depression, bone loss, muscle loss, and several other systemic conditions when a man has persistent symptoms plus biochemical deficiency, commonly total testosterone below 350 ng/dL or free testosterone below 100 pg/mL on accurate morning testing. A low number alone is not a diagnosis, and symptoms alone are not enough either. Once deficiency is confirmed and LH and FSH are measured, the clinical question becomes which related conditions are present, and whether treatment is likely to help.

Key takeaways

• Male hypogonadism requires both persistent symptoms and biochemical deficiency, usually total testosterone below 350 ng/dL or free testosterone below 100 pg/mL on a morning 07:00 to 11:00 blood draw.^{[1] [2]}
• LH and FSH must be measured with testosterone. High LH plus low testosterone points to primary hypogonadism, while low or normal LH plus low testosterone points to secondary or functional hypogonadism. Primary hypogonadism usually requires TRT, whereas secondary and functional hypogonadism with low or normal LH, particularly LH below 8 mIU/mL, is usually treated first with Enclomiphene when appropriate.^{[1] [2]}
• A meta analysis of 27 randomized trials including 1,890 men found testosterone therapy improved mild depressive symptoms, but the TRAVERSE program did not support testosterone as an effective treatment for most men with clinical depressive disorders.^{[3] [8]}
• Severe hypogonadism, total testosterone below 3.5 nmol/L, is frequently associated with bone loss and osteoporosis independent of age, and testosterone therapy raises bone mineral density most clearly at the lumbar spine.^{[1] [4]}
• TRAVERSE randomized 5,246 men and found testosterone therapy was noninferior to placebo for major adverse cardiovascular events over a mean 33 months, but atrial fibrillation occurred in 3.5% versus 2.4%, with higher pulmonary embolism and acute kidney injury signals in the treatment group.^[8]
• Randomized evidence does not show increased prostate cancer risk or meaningful worsening of lower urinary tract symptoms with testosterone therapy, but active or advanced prostate cancer remains a contraindication.^{[2] [6] [7] [8]}

Depression and mood

Low testosterone and depression are linked in observational studies, but the specific causal relationship remains unclear.^{[1] [3]}

Quality of life means a man’s day to day physical, sexual, and emotional functioning.

According to the Endocrine Society guideline, mood symptoms belong in the clinical picture of male hypogonadism, but they are not specific enough to establish the diagnosis on their own.^[1] Fatigue, low motivation, irritability, and low mood overlap with primary depressive disorders, sleep disorders, and chronic medical illness. For the formal diagnostic framework, see What is low testosterone? The clinical definition most men and many doctors get wrong.

What the evidence shows for mood

A 2019 JAMA Psychiatry meta analysis found that testosterone treatment improved depressive symptoms in hypogonadal men, with the clearest benefit in men who had milder depressive symptoms rather than severe psychiatric disease.^[3] That distinction matters clinically. Low testosterone related mood symptoms appear more likely to improve when they are part of a broader syndrome that also includes sexual symptoms, reduced vitality, or body composition changes.

This is why “low testosterone and depression” should be framed carefully. Men with confirmed hypogonadism often report better energy, less emotional flattening, and better well being after treatment, but testosterone is not a substitute for a full mental health assessment.^{[1] [3]}

What testosterone can and cannot do for depression

The TRAVERSE program found that testosterone therapy did not appear to represent an effective treatment option for most men with clinical depressive disorders.^[8] In other words, a man with major depression still needs standard psychiatric care, even if low testosterone is also present.

According to current guideline based practice, the most defensible position is this. If a man has persistent symptoms, documented biochemical deficiency, and other manifestations of hypogonadism, testosterone treatment may improve mild depressive symptoms that are part of the hormonal syndrome. If he has severe or persistent depression, conventional psychiatric treatment remains essential.^{[1] [3]}

Bone loss and fracture risk

Severe testosterone deficiency is frequently associated with bone loss and osteoporosis, independent of age.^{[1] [4]}

Osteopenia means bone density below normal, but not yet in the osteoporosis range. Osteoporosis means bone strength is low enough to meaningfully increase fracture risk.

The relationship between testosterone and bone loss is not all or nothing. Mild hypogonadism has only a weak association with osteopenia and osteoporosis, but the signal becomes much stronger when deficiency is severe, especially when total testosterone falls below about 3.5 nmol/L.^[1] That is why men with marked deficiency deserve a higher level of attention to skeletal health.

How low testosterone affects bone

Bone is a metabolically active tissue that continually remodels itself. Testosterone supports bone formation directly and also contributes through aromatization to estradiol, which is important for male bone maintenance. When androgen exposure falls substantially, bone turnover can shift in an unfavorable direction, and cumulative bone loss follows.^[1]

According to the Testosterone Trials, testosterone treatment increased volumetric bone mineral density and estimated bone strength in older men with low testosterone, with the most pronounced effect at the spine.^[4] This is the main clinical reason that “testosterone and bone loss” belongs in any serious discussion of male hypogonadism.

What treatment can realistically achieve for bone

Three meta analyses summarized in guidelines show a positive effect of testosterone replacement on bone mineral density, particularly at the lumbar spine.^[1] That supports TRT as a useful adjunct in hypogonadal men who also have low bone density.

What testosterone has not yet convincingly shown is a reduction in fractures. The fracture endpoint requires larger and longer studies than are currently available. For men at high fracture risk, anti resorptive treatment remains first line bone therapy. Testosterone is supplementary when true hypogonadism is present, not a replacement for standard osteoporosis management.^{[1] [4]}

Muscle loss and physical function

Testosterone helps maintain lean mass, and testosterone therapy in hypogonadal men consistently increases muscle mass while reducing fat mass.^{[1] [5]}

Sarcopenia means age related loss of muscle mass and physical function.

Testosterone’s anabolic role is well established. Men with deficiency often notice reduced muscle size, slower recovery, increased fat accumulation, and lower exercise tolerance. This makes “testosterone and muscle loss” one of the most clinically relevant low testosterone related conditions, especially in older men or in men already trending toward frailty.^{[1] [5]}

Body composition is not the same as function

The Testosterone Trials showed that treatment improved body composition and had modest positive effects on walking distance, but the evidence for a large functional improvement in older men remains limited.^[5] That distinction is important. Gaining lean mass on a scan or reducing fat mass does not automatically translate into substantial gains in strength, balance, or real world mobility.

According to the Endocrine Society guideline, clinicians should expect a clearer effect on body composition than on advanced functional outcomes such as strength dependent tasks in elderly men.^[1] In plain terms, TRT can improve the biological substrate for strength, but it cannot replace training.

Why exercise still determines the outcome

For older men and for sarcopenia prevention, the best approach remains the combination of testosterone correction, when hypogonadism is confirmed, and structured strength training.^{[1] [5]} Resistance exercise provides the mechanical stimulus that turns added anabolic potential into practical gains.

This is also the right way to set expectations. TRT can help reverse part of the low testosterone and muscle loss pattern. It is less reliable as a stand alone method for restoring meaningful physical performance in elderly men who do not also train.^[5]

Urinary symptoms and prostate cancer

Current randomized evidence does not show that testosterone therapy worsens lower urinary tract symptoms or increases prostate cancer risk in men without active or advanced disease.^{[2] [6] [7] [8]}

LUTS means lower urinary tract symptoms, such as urgency, frequency, nocturia, weak stream, or incomplete emptying. BPH means benign prostatic hyperplasia, which is noncancerous enlargement of the prostate.

What the data show for LUTS and BPH

A 2016 European Urology meta analysis found no significant worsening of LUTS in testosterone treated men compared with placebo, and some storage symptoms may improve rather than deteriorate.^[6] This is one of the more useful corrections to outdated counseling, because many men are still told that any testosterone exposure will automatically worsen urination.

The main caution is severe baseline symptoms. Men with an International Prostate Symptom Score above 19 have usually been excluded from trials, so the evidence is thinner in that group.^{[2] [6]} That is a data gap, not proof of harm.

What the data show for prostate cancer

The AUA guideline and pooled trial data do not support the old idea that appropriately prescribed testosterone “feeds” prostate cancer.^{[2] [7]} A systematic review of randomized trials found no evidence of increased PSA driven cancer detection or prostate cancer events with treatment.^[7]

The strongest recent evidence comes from TRAVERSE. In 5,246 men followed for a mean of 33 months, prostate cancer incidence did not differ between the testosterone and placebo groups.^[8] That is the most clinically relevant answer available to the question of “testosterone and prostate cancer.”

There are still two important caveats. First, active or advanced prostate cancer remains a contraindication to TRT.^{[1] [2]} Second, some observational work has suggested that men with very low free testosterone may have a nonsignificant tendency toward higher grade disease at diagnosis, which is very different from saying TRT causes prostate cancer.^[2] For lab interpretation and PSA monitoring, see The complete low testosterone testing guide.

TRT cardiovascular safety

The TRAVERSE trial showed that testosterone therapy was noninferior to placebo for major adverse cardiovascular events in 5,246 men followed for a mean of 33 months.^[8]

MACE means heart attack, stroke, or cardiovascular death.

The TRAVERSE trial, published in the New England Journal of Medicine, was designed specifically to answer the heart safety question that older studies could not settle.^[8] Men in the study had hypogonadism plus either established cardiovascular disease or elevated cardiovascular risk, making the results directly relevant to real world practice.

What TRAVERSE settled

The primary endpoint occurred in 7.0% of the testosterone group and 7.3% of the placebo group, which met the prespecified noninferiority standard.^[8] That means current evidence does not support the claim that TRT broadly increases heart attack or stroke risk when used appropriately in hypogonadal men.

This matters because TRT cardiovascular safety had been distorted for years by small, conflicting studies and heterogeneous prescribing patterns. TRAVERSE is now the anchor trial in this discussion.^[8] The TRAVERSE Diabetes substudy did not materially change this cardiovascular safety interpretation in men with diabetes.

What risks still need discussion

Noninferior for MACE does not mean risk free. TRAVERSE found a higher incidence of atrial fibrillation, 3.5% versus 2.4%, along with higher pulmonary embolism and acute kidney injury signals in the testosterone arm.^[8] Those findings should be part of informed consent, especially for men with prior deep vein thrombosis, pulmonary embolism, arrhythmia, or kidney disease.

The practical conclusion is narrower than many headlines suggest. TRT did not raise overall major cardiovascular event risk in the trial, but it did produce specific safety signals that require individualized risk assessment and ongoing monitoring.^[8]

Sleep apnea and erythrocytosis

Current evidence does not show that testosterone therapy causes persistent obstructive sleep apnea, but erythrocytosis is the most common adverse effect of treatment and usually becomes evident within 3 to 12 months.^{[1] [7] [9]}

Obstructive sleep apnea means repeated airway collapse during sleep, causing intermittent drops in oxygen. Erythrocytosis means an abnormally high red blood cell concentration, usually tracked by hematocrit.

Sleep apnea is not an automatic reason to avoid treatment

A randomized placebo controlled trial in men with severe obstructive sleep apnea found a temporary reduction in oxygen saturation at 7 weeks after testosterone treatment, but this effect was no longer present by 18 weeks.^[9] Current guidance therefore does not treat sleep apnea as an absolute contraindication to testosterone therapy.^[1]

In clinical practice, the better approach is parallel management. Men with both hypogonadism and sleep apnea should have both conditions addressed, rather than assuming one diagnosis fully explains the other. In trial data, men with obstructive sleep apnea treated with CPAP had better outcomes when testosterone gel was added than with CPAP alone, but testosterone is not a primary treatment for sleep apnea. That is especially important because untreated sleep apnea can also worsen fatigue, low mood, sexual symptoms, and cardiometabolic risk.

Why hematocrit has to be monitored

According to the Endocrine Society guideline, stimulation of erythropoiesis is a normal biologic action of testosterone, which is why hematocrit monitoring is mandatory during treatment.^[1] Elevated hematocrit is the most common adverse effect of TRT, and evidence does not show that values up to 54% clearly cause adverse events. Above 54%, the association with cardiovascular events becomes more concerning, even if the evidence is still not definitive.^{[1] [7]}

Formulation matters. Injectable testosterone is more likely than topical treatment to drive erythrocytosis, and TRAVERSE studied gel based TRT, not injections.^{[7] [8]} That means the hematocrit safety profile seen in TRAVERSE should not be assumed to apply equally to injectable regimens.

Management is usually straightforward. Options include dose reduction, switching formulation, or venesection when needed.^[1] For the lab sequence and follow up testing strategy, see The complete low testosterone testing guide.

Genetic conditions linked to low testosterone

Genetic disorders are uncommon but important low testosterone related conditions, and Klinefelter syndrome is the most prevalent genetic cause, affecting about 1 in 500 to 1,000 male births.^{[2] [10]}

Primary hypogonadism means the testes cannot produce enough testosterone even when the brain is sending the correct signals.

Klinefelter syndrome is common and often missed

A national registry study found a population prevalence in the expected range, but contemporary guidelines note that fewer than half of affected men are ever diagnosed.^{[2] [10]} Klinefelter syndrome, usually 47,XXY, is associated with primary hypogonadism, infertility, and possible cognitive or psychosocial effects.

These men do not fit the same management pathway as men with acquired, potentially reversible hypogonadism. The condition is lifelong, and fertility counseling is central from the start.

Other inherited causes also change management

According to guideline based classification, other genetic causes include myotonic dystrophy, disorders of sex development, and Kennedy disease, which involves an androgen receptor CAG repeat expansion.^{[1] [2]} These conditions are clinically important because they can alter not only testosterone production, but also androgen action at the tissue level.

The key implication is that inherited forms of hypogonadism usually require a different long term plan than acquired functional cases. For the treatment importance of this distinction, see Primary vs secondary hypogonadism: where the problem starts and why it changes everything.

Myth vs fact

Myth: TRT causes prostate cancer.

Fact: Current randomized evidence, including meta analyses and the 5,246 man TRAVERSE trial, does not show increased prostate cancer risk with testosterone therapy in appropriately selected men, although active or advanced prostate cancer remains a contraindication.^{[2] [7] [8]}

Myth: Testosterone always worsens BPH and urination.

Fact: Multiple studies and meta analyses show no significant worsening of lower urinary tract symptoms with TRT, and some storage symptoms may improve. The main uncertainty is in men with severe baseline LUTS, because they are often excluded from trials.^[6]

Myth: Testosterone is a treatment for major depression.

Fact: Testosterone therapy can improve mild depressive symptoms in men with confirmed hypogonadism, but it did not appear to be an effective treatment for most men with clinical depressive disorders in the TRAVERSE program.^{[3] [8]}

Myth: Sleep apnea means a man cannot use testosterone.

Fact: Sleep apnea is not an absolute contraindication. Available data do not show persistent worsening caused by TRT, although monitoring is sensible because one randomized trial found a temporary decline in oxygen saturation early in treatment.^{[1] [9]}

Myth: A high hematocrit on TRT means immediate danger.

Fact: Erythrocytosis is the most common adverse effect of testosterone therapy and is usually manageable with dose adjustment, formulation change, or venesection. The main action point is careful monitoring, especially if hematocrit rises above 54%.^{[1] [7]}

Bottom line

Low testosterone related conditions are real. In men with confirmed hypogonadism, low testosterone is linked to depressive symptoms, bone loss, muscle loss, reduced quality of life, and several treatment relevant safety questions, while modern evidence does not show increased prostate cancer risk or overall major cardiovascular event risk from appropriately prescribed TRT.^{[1] [8]} The key is correct diagnosis first, because a low testosterone result alone is not enough, and LH and FSH are required to classify the cause before any treatment decision is made. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers a thorough diagnostic workup with an advanced lab panel measured by LC-MS/MS, or a review of existing lab results, including uploaded outside testing, to determine whether symptoms truly fit male hypogonadism and whether the pattern is primary, secondary, or functional. Licensed providers build individualized treatment plans with Enclomiphene as first line for eligible men, the Enclomiphene plus Tadalafil combination tablet when erection or urinary symptoms are also present, and ongoing monitoring with follow up labs after the first month and then every 6 months.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology. 2018;200:423-432. PMID: 29601923
3. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA psychiatry. 2019;76:31-40. PMID: 30427999
4. Isidori AM, Giannetta E, Pozza C, et al. Androgens, cardiovascular disease and osteoporosis. Journal of endocrinological investigation. 2005;28:73-9. PMID: 16550728
5. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. The New England journal of medicine. 2016;374:611-24. PMID: 26886521
6. Kohn TP, Mata DA, Ramasamy R, et al. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. European urology. 2016;69:1083-90. PMID: 26874809
7. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2010;95:2560-75. PMID: 20525906
8. Rochira V. Late-onset Hypogonadism: Bone health. Andrology. 2020;8:1539-1550. PMID: 32469467
9. Hoyos CM, Killick R, Yee BJ, et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clinical endocrinology. 2012;77:599-607. PMID: 22512435
10. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. The Journal of clinical endocrinology and metabolism. 2003;88:622-6. PMID: 12574191